



ASX Release

DIRECTOR'S CLARIFICATION ON SHARE SALE

On the 24th December, Eastland's Non-Executive Director Mr Michael Stewart notified the market that he had disposed of 6,666,666 EMS shares via an off market transfer. The Company has received a number of calls from shareholders asking whether Mr Stewart was still committed to the Company.

Mr Stewart's commitment to the Company has not waived; he remains a board member and believes strongly in the sublingual malaria project and the positive impact it can have on the lives of young children with severe or complicated malaria. The sale of the shares was for personal reasons and was in no way an indication that Mr Stewart had lost any confidence whatsoever in the Company, its management or its main malaria project.

Further to Mr Stewart's 240,000 EMSOB options and 150,001 EMS shares. Mr Stewart still retains 200,000 convertible notes (convertible to 6,666,666 shares).

Further information:

Stephen Carter
CEO
Eastland Medical Systems Ltd
t: +61 8 6142 5555
sjcarter@eastlandmedical.com.au

Highlights

- **Positive results achieved from Phase I multi and single dose clinical studies for ArTiMist™ indicating the formulation was well tolerated and showed no adverse effects in any of the study subjects.**
- **Very positive successful results achieved from Phase IIa ArTiMist™ trial Clinical Field Trial completed in February 2010 in Rwanda.**